These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The antimetastatic effects of BJA-II on nude mice with highly metastatic human ovarian carcinoma].
    Author: Gao YL, Xu SH, Mu HZ.
    Journal: Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):404-7, 444-5. PubMed ID: 8001416.
    Abstract:
    Nude mice with highly metastatic human ovarian carcinoma were treated with BJA-II. This new agent was made in our institute. Twenty-four experimental mice were divided into 4 groups with 6 mice each. The mice, according to the treatment given them, were designated as: the BJA-II group, the cisplatin group, the group with combination therapy and the control group. Treatment began on the 2nd day after tumor transplantation. For BJA-II, a dose of 16 mg per mouse per day was administered orally. The total dose each mouse received by the 53rd day was 848mg. The tumor growth inhibition rate was found to be 63.7% in the BJA-II group; the transplanted tumors disappeared in 2 mice. No significant difference in average tumor weight was found between the BJA-II group and the control group (P < 0.05). The antimetastatic effect of BJA-II (1 mouse with metastasis) was higher than that of the control group (4 mice with metastasis). The influences on the immunofunction of the host were observed: the increase of the peripheral WBC count, the increase of NK cell activity, the increase in the ratio of spleen weight to body weight, and the histiocyte increase in the lymph node sinuses, etc. All of these findings were better demonstrated in the BJA-II group than in the cisplatin group. The results indicate that BJA-II is provided with the effectiveness of inhibiting tumor growth, is antimetastatic and is capable of increasing the immunofunction of the host.
    [Abstract] [Full Text] [Related] [New Search]